B. Klein, K. Tarte, and M. Jourdan, Survival and Proliferation Factors of Normal and Malignant Plasma Cells, International Journal of Hematology, vol.276, issue.2, pp.106-113, 2003.
DOI : 10.1007/BF02983377
URL : https://hal.archives-ouvertes.fr/inserm-00130900

B. Klein, X. Zhang, and M. Jourdan, Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6, Blood, vol.73, pp.517-526, 1989.

M. Jourdan, X. Zhang, M. Portier, J. Boiron, R. Bataille et al., IFN-alpha induces autocrine production of IL-6 in myeloma cell lines, J Immunol, vol.147, pp.4402-4407, 1991.

D. Jelinek, T. Witzig, and B. Arendt, A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth, J Immunol, vol.159, pp.487-496, 1997.

Y. Wang, D. Vos, J. Jourdan, and M. , Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells, Oncogene, vol.21, issue.16, pp.2584-2592, 2002.
DOI : 10.1038/sj.onc.1205355

K. Mahtouk, D. Jm, and J. Vos, An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis, Blood, vol.103, issue.5, 2003.
DOI : 10.1182/blood-2003-05-1510
URL : https://hal.archives-ouvertes.fr/inserm-00130207

B. Klein, J. Wijdenes, and X. Zhang, Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia, Blood, vol.78, pp.1198-1204, 1991.

R. Bataille, B. Barlogie, and Z. Lu, Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma, Blood, vol.86, pp.685-691, 1995.

K. Tarte, D. Vos, J. Thykjaer, and T. , Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts, Blood, vol.100, pp.1113-1122, 2002.

D. Vos, J. Thykjaer, T. Tarte, and K. , Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays, Oncogene, vol.99, issue.44, pp.6848-6857, 2002.
DOI : 10.1038/sj.onc.1205868

D. Vos, J. Couderc, G. Tarte, and K. , Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays, Blood, vol.98, issue.3, pp.771-780, 2001.
DOI : 10.1182/blood.V98.3.771

P. Schneider, F. Mackay, and V. Steiner, BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth, The Journal of Experimental Medicine, vol.85, issue.11, pp.1747-1756, 1999.
DOI : 10.1126/science.7537388

P. Moore, O. Belvedere, and A. Orr, BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator, Science, vol.285, issue.5425, pp.260-263, 1999.
DOI : 10.1126/science.285.5425.260

F. Mackay, P. Schneider, P. Rennert, J. Browning, . Baff et al., APRIL: A Tutorial on B Cell Survival, Annual Review of Immunology, vol.21, issue.1, pp.231-264, 2003.
DOI : 10.1146/annurev.immunol.21.120601.141152

F. Mackay and J. Browning, BAFF: A fundamental survival factor for B cells, Nature Reviews Immunology, vol.2, issue.7, pp.465-475, 2002.
DOI : 10.1038/nri844

M. Hahne, T. Kataoka, and M. Schroter, APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth TALL-1 is a novel member of the TNF family that is down-regulated by mitogens, Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL, pp.1185-1190680, 1998.

G. Yu, T. Boone, and J. Delaney, APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI, Nat Immunol. Curr Biol, vol.110, issue.21, pp.252-256785, 2000.

J. Stein, M. Lopez-fraga, and F. Elustondo, APRIL modulates B and T cell immunity Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response The prosurvival Bcl, J Clin Invest. J Exp Med. Zong WX, vol.109192, issue.242, pp.1587-1598953, 2000.

C. Chen, L. Edelstein, and C. Gelinas, The Rel/NF-kappa B Family Directly Activates Expression of the Apoptosis Inhibitor Bcl-xL, Molecular and Cellular Biology, vol.20, issue.8, pp.2687-2695, 2000.
DOI : 10.1128/MCB.20.8.2687-2695.2000

M. Batten, J. Groom, and T. Cachero, BAFF mediates survival of peripheral immature B lymphocytes Aberrant expression of Blymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival, J Exp Med. Blood, vol.192100, issue.28, pp.1453-14662973, 2000.

C. Kern, J. Cornuel, and C. Billard, Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway BLyS and BLyS receptor expression in non-Hodgkin's lymphoma, Blood. Exp Hematol, vol.3030, pp.135-141, 2002.

X. Zhang, J. Gaillard, and N. Robillard, Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma, Blood, vol.83, pp.3654-3663, 1994.

Z. Lu, X. Zhang, and C. Rodriguez, Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells Mechanism of BLyS action in B cell immunity, Blood. Cytokine Growth Factor Rev, vol.8513, issue.33, pp.2521-252719, 1995.

D. Avery, S. Kalled, and J. Ellyard, BAFF selectively enhances the survival of plasmablasts generated from human memory B cells Granulocyte-macrophage colonystimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells, J Clin Invest. Blood, vol.11276, issue.35, pp.286-2972599, 1990.

M. Ferlin, N. Noraz, C. Hertogh, J. Brochier, N. Taylor et al., Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin- 6-independent transduction pathway, Br J Haematol, vol.111, pp.626-634, 2000.

J. Hsu, Y. Shi, L. Hu, M. Fisher, T. Franke et al., Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses, Oncogene, vol.21, issue.9, pp.1391-1400, 2002.
DOI : 10.1038/sj.onc.1205194

E. Claudio, K. Brown, S. Park, H. Wang, and U. Siebenlist, BAFF-induced NEMO-independent processing of NF-??B2 in maturing B cells, Nature Immunology, vol.3, issue.10, pp.958-965, 2002.
DOI : 10.1038/ni842

L. Xu and H. Shu, TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kappa B activation and IL-10 production

A. Mukhopadhyay, J. Ni, Y. Zhai, G. Yu, and B. Aggarwal, Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase, J Immunol. J Biol Chem, vol.169274, issue.40, pp.6883-688915978, 1999.

C. Mitsiades, N. Mitsiades, and V. Poulaki, Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells, Oncogene. Immunity, vol.2110, issue.42, pp.5673-5683105, 1999.

B. Zhang, I. Gojo, and R. Fenton, Myeloid cell factor-1 is a critical survival factor for multiple myeloma, Blood, vol.99, issue.6, pp.1885-1893, 2002.
DOI : 10.1182/blood.V99.6.1885

H. Wiklund, Expression of the bcl-2 family of pro-and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6(IL-6)-induced growth and survival, Eur J Haematol, vol.69, pp.76-89, 2002.

M. Jourdan, D. Vos, J. Mechti, N. Klein, and B. , Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1, Cell Death and Differentiation, vol.7, issue.12, pp.1244-1252, 2000.
DOI : 10.1038/sj.cdd.4400758
URL : https://hal.archives-ouvertes.fr/inserm-00130981

M. Jourdan, J. Veyrune, J. Vos, N. Redal, G. Couderc et al., A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells, Oncogene, vol.22, issue.19, pp.2950-2959, 2003.
DOI : 10.1038/sj.onc.1206423
URL : https://hal.archives-ouvertes.fr/inserm-00130855

A. Novak, J. Darce, and B. Arendt, is an essential survival protein of human myeloma cells Expression of BCMA, TACI, and BAFF- R in multiple myeloma: a mechanism for growth and survival, Blood. Blood, vol.100, issue.48, pp.194-199, 2002.

C. Ware, . April, M. Gras, Y. Laabi, and G. Linares-cruz, BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes, J Exp Med. Int Immunol, vol.1927, issue.50, pp.35-381093, 1995.

S. Xu and K. Lam, B-Cell Maturation Protein, Which Binds the Tumor Necrosis Factor Family Members BAFF and APRIL, Is Dispensable for Humoral Immune Responses, Molecular and Cellular Biology, vol.21, issue.12, pp.4067-4074, 2001.
DOI : 10.1128/MCB.21.12.4067-4074.2001

J. Thompson, S. Bixler, and F. Qian, BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF, Science, vol.293, issue.5537, pp.2108-2111, 2001.
DOI : 10.1126/science.1061965

P. Schneider, H. Takatsuka, and A. Wilson, Maturation of Marginal Zone and Follicular B Cells Requires B Cell Activating Factor of the Tumor Necrosis Factor Family and Is Independent of B Cell Maturation Antigen, The Journal of Experimental Medicine, vol.269, issue.11, pp.1691-1697, 2001.
DOI : 10.1111/j.1600-065X.2000.imr017517.x

M. Yan, J. Brady, and B. Chan, Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency, Current Biology, vol.11, issue.19, pp.1547-1552, 2001.
DOI : 10.1016/S0960-9822(01)00481-X

J. Gross, S. Dillon, and S. Mudri, TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease, Immunity, vol.15, issue.2, pp.289-302, 2001.
DOI : 10.1016/S1074-7613(01)00183-2

H. Shu, J. H. Hatzoglou, A. Roussel, J. Bourgeade, and M. , TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway crosstalk, Proc Natl Acad Sci U S A. J Immunol. Science. Blood, vol.9716527899, issue.58, pp.9156-91611322, 1997.

D. Vos, J. , J. M. Tarte, K. Jasmin, C. Klein et al., JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma, Br J Haematol. Oncogene, vol.10920, issue.61, pp.823-8285991, 2000.

Y. Shi, J. Hsu, L. Hu, J. Gera, A. Lichtenstein et al., Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6 Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells, J Biol Chem. Int J Oncol, vol.27713, pp.15712-15720397, 1998.

Y. Tu, F. Xu, and J. Liu, Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide, Blood, vol.88, pp.1805-1812, 1996.

Z. Gu, J. Vos, and C. Rebouissou, Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases, Leukemia. Arthritis Rheum, vol.1444, issue.66, pp.188-1971313, 2000.

J. Zhang, V. Roschke, and K. Baker, Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus, The Journal of Immunology, vol.166, issue.1, pp.6-10, 2001.
DOI : 10.4049/jimmunol.166.1.6

W. Stohl, N. Mitsiades, C. Mitsiades, and P. Richardson, Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications NF-kappa B as a therapeutic target in multiple myeloma, Curr Opin Rheumatol. Blood. J Biol Chem, vol.14101277, issue.70, pp.522-5282377, 2002.